5. Conclusion
cardiac death
STENOSES, CARDIAC DEATH, DEGENERATED
In conclusion, we could demonstrate that the interventional therapy of degenerated SVGs by SExS is safe, even in patients with ACS. The SExS showed a clinical benefit over BExS regarding MACE rate at 30-days as well as at one-year follow-up, in particular concerning the rate of MI, TLR, and TVR. Furthermore, cardiac death occurred significantly later after treatment with SExS. The history of previous SVG intervention was an independent risk factor in both groups. Our findings should be further investigated in larger multicentric randomized trials and might enable an alternative interventional strategy in the treatment of SVG stenoses.